Jiajun Liu

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

Katherine R. Tuttle, Frank C. Brosius, Sharon G. Adler et al. · Nephrology Dialysis Transplantation · 2017 · 266 citations · Full text

The Genetic Duet of <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer

Jiajun Liu, Rengyun Liu, Xiaopei Shen et al. · Journal of Nuclear Medicine · 2019 · 122 citations · Full text

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

Nathaniel J. Rhodes, Joseph L. Kuti, David P. Nicolau et al. · Antimicrobial Agents and Chemotherapy · 2015 · 59 citations · Full text

Improved Survival, Logistic Analysis, Drug Resistance +20

Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?

Sean N. Avedissian, Gwendolyn Pais, Jiajun Liu et al. · Clinical Infectious Diseases · 2019 · 54 citations

Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model

Gwendolyn Pais, Jiajun Liu, Sean N. Avedissian et al. · Journal of Antimicrobial Chemotherapy · 2019 · 54 citations · Full text